Illinois Municipal Retirement Fund Grows Stock Holdings in Eli Lilly and Company $LLY

Illinois Municipal Retirement Fund increased its position in Eli Lilly and Company (NYSE:LLY) by 14.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,959 shares of the company’s stock after acquiring an additional 6,950 shares during the period. Eli Lilly and Company makes up about 0.7% of Illinois Municipal Retirement Fund’s investment portfolio, making the stock its 17th biggest position. Illinois Municipal Retirement Fund’s holdings in Eli Lilly and Company were worth $51,469,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC raised its stake in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. Schnieders Capital Management LLC. increased its holdings in Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $356,000. Finally, Nebula Research & Development LLC acquired a new position in Eli Lilly and Company during the second quarter worth about $749,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LLY has been the topic of several recent research reports. Leerink Partners upped their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Sanford C. Bernstein lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research report on Tuesday. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,283.64.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,156.67 on Thursday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm has a 50 day moving average price of $1,110.32 and a 200 day moving average price of $1,035.14. The company has a market cap of $1.09 trillion, a price-to-earnings ratio of 41.09, a PEG ratio of 1.41 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter last year, the firm posted $3.34 earnings per share. Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 35.5 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly is reportedly nearing a deal to acquire psychedelic drugmaker AtaiBeckley, a move that could broaden its pipeline and reinforce Lilly’s strategy of expanding beyond obesity and diabetes. Reuters: Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley
• Positive Sentiment: A Bloomberg/Economist-style reassessment of Eli Lilly’s business highlighted the company as a pharma innovator, which can support sentiment around its premium valuation and long-term growth profile. The Economist: Eli Lilly is reinventing the pharma business
• Positive Sentiment: Eli Lilly’s selpercatinib won full FDA approval for use in solid tumors, giving the company another commercial catalyst in oncology. Yahoo Finance: Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors
• Neutral Sentiment: The broader healthcare sector moved higher, providing some tailwind to Lilly shares even as company-specific headlines remained mixed. Yahoo Finance: Sector Update: Healthcare Stocks Advance Late Afternoon
• Negative Sentiment: New reports said Lilly’s obesity pill is still trailing Novo Nordisk’s Wegovy in U.S. prescription momentum, reinforcing fears that Lilly is behind in the oral weight-loss race. Yahoo Finance: Lilly’s Obesity Pill Trails Wegovy
• Negative Sentiment: A Florida hospital sued Lilly over its move to suspend access to a federal drug discount program, adding legal and reputational risk around pricing and access. The Indiana Lawyer: Florida hospital sues Lilly over move to suspend access to federal drug discount program
• Negative Sentiment: Coverage of Lilly’s obesity-pill rollout also suggested the launch is lagging behind Novo’s competing product, which may weigh on expectations for near-term market share gains. WSJ: It’s been three months since Lilly launched its obesity pill. Most people are taking Novo’s pill instead.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.